Navigation Links
GlaxoSmithKline and AFFiRiS Sign an Exclusive Licence and Option Agreement for Therapeutic Alzheimer's Disease Candidate Vaccines
Date:10/23/2008

VIENNA, Austria, October 23 /PRNewswire/ -- GlaxoSmithKline Biologicals S.A. (GSK) and AFFiRiS GmbH announced today the execution of a collaboration agreement granting GSK exclusive rights to AFFiRiS's Alzheimer's disease vaccine programmes, aimed at treating Alzheimer's by targeting beta-amyloid.

As part of the agreement GSK is acquiring exclusive rights to develop and commercialise two Alzheimer's disease vaccine candidates that are based on AFFiRiS AFFiTOPE technology and are currently in Phase I clinical development. AFFiRiS is also granting GSK an exclusive option to develop and commercialise alternative Alzheimer's disease vaccine candidates which are in preclinical development.

Under the terms of the agreement, AFFiRiS will receive an up-front payment of EUR 22.5 million (GBP17.5 million) and could be eligible for future milestone payments and royalties. The total potential value of the agreement could reach EUR 430 million (GBP334 million) in the event of full commercial success of the candidate vaccines. This agreement is subject to governmental authority approval.

Central to the deal is the AFFiRiS AFFiTOPE technology which allows the design of proteins with very specific binding characteristics that are ideally suited for the development of vaccines against disease-causing "rogue" human proteins such as beta-amyloid which is central to the pathology of Alzheimer's disease.

Commenting on the agreement, Walter Schmidt, co-founder and CEO of AFFiRiS, stated: "We are pleased that we could secure GSK Biologicals, one of the world's leading vaccine companies, in collaborating on the development our Alzheimer's disease vaccine programs. This deal brings together two companies with strong innovation, vaccine development and commercialisation capabilities and experience."

Jean Stephenne, President and General Manager of GlaxoSmithKline Biologicals, said "We are impressed with the AFFiRiS technology - combined with our expe
'/>"/>

SOURCE AFFiRiS GmbH, GlaxoSmithKline Biologicals (GSKBiologicals)
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. GlaxoSmithKline and Cellzome Announce Major Strategic Alliance
2. GlaxoSmithKline Offers New Purchasing Options to Help Employers Overcome Barriers to Pandemic Stockpiling of Relenza(R)
3. GlaxoSmithKline To Post Quarterly US Grants Report
4. GlaxoSmithKline - Q2 Results and Strategy Update - Interview with CEO
5. Exelixis and GlaxoSmithKline Agree to Successfully Conclude Six-Year Discovery and Development Collaboration
6. CDC Immunization Advisory Committee Recommends Two New Pediatric Vaccines from GlaxoSmithKline
7. FDA Approves GlaxoSmithKlines AVODART(R) in Combination with Tamsulosin for the Treatment of Symptomatic Enlarged Prostate
8. GlaxoSmithKline and Mpex Pharmaceuticals Form Alliance to Develop Novel Efflux Pump Inhibitors for Use Against Serious Gram-Negative Infections
9. GlaxoSmithKline Signs Licensing Agreement With Compendia Bioscience
10. GlaxoSmithKline Named A Top Employer for Promoting Healthy Lifestyles
11. GlaxoSmithKline Commences Tender Offer to Acquire Sirtris Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Aug. 21, 2014  China Cord Blood Corporation (NYSE: ... to release financial results for the first quarter of ... market close in the US.  The ... ET on Friday, August 29, 2014 to discuss its ... Company,s recent developments, followed by a question and answer ...
(Date:8/21/2014)... August 21, 2014 Gallus ... contract development and manufacturing organization (CMO) announced today ... Inc., an oncology company focused on the development ... to manufacture the anti-prostate specific membrane antigen (PSMA) ... candidate. Under the agreement the antibody will ...
(Date:8/20/2014)... analysis of patented university inventions licensed to biotechnology ... to commercialization. To open these roadblocks, the researchers ... during the discovery stage could lead to faster ... frequently derived from discoveries made in university laboratories ... known during clinical trials, which have a high ...
(Date:8/20/2014)... Livermore, California (PRWEB) August 20, 2014 ... to develop and apply the most complete climate ... challenging and demanding climate change issues. , Eight ... combining forces with the National Center for Atmospheric ... in the new effort. Other participating national laboratories ...
Breaking Biology Technology:China Cord Blood Corporation to Report First Quarter of Fiscal 2015 Financial Results 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3New Project Is the ACME of Addressing Climate Change 2New Project Is the ACME of Addressing Climate Change 3
... you doing to become a better husband or wife, daughter ... to turn my e-mail into a confessional. I've just been ... who have been making that relationship work, it's funny how ... Sounds like some idealized family. , ,"Oh great!" you're thinking. ...
... Madison, Wis. - One of Wisconsin's most prominent ... its name changed. This move will result in a ... potential opportunites for the state's life science industry, increase ... for the firm's investors. , , Genzyme Corp. , ...
... old Institute of Paper Chemistry might have left Appleton more ... feel the void. , ,Organizers of the new ... void Wednesday with the PTTC's grand opening in downtown Green ... rolling out more than 6.4 million tons of paper and ...
Cached Biology Technology:Taking your work home 2Taking your work home 3Genzyme acquistion of Bone Care approved, significant impact forecast 2Genzyme acquistion of Bone Care approved, significant impact forecast 3Genzyme acquistion of Bone Care approved, significant impact forecast 4Paper technology transfer center opens in Green Bay 2Paper technology transfer center opens in Green Bay 3
(Date:8/21/2014)... the pancreas digesting itself resulting in severe abdominal pain, ... around 20,000 patients are diagnosed with the disease resulting ... treatment is restricted to intravenous fluid and nutritional support. ... Life Sciences, who led the research, said "The major ... stones and excessive alcohol intake combined with a high ...
(Date:8/20/2014)... 20, 2014 /CNW/ -  Issue Serious ... quickly become life threatening for some children.    ... million Canadians have food allergies and this number may be ... children are estimated to have food allergies.  ... irritations and hives to breathing difficulties and loss of consciousness. ...
(Date:8/20/2014)... Institutes of Health has awarded the Oklahoma Medical Research ... research on anthrax and the bacteria,s effects on humans. ... Ph.D., and his colleagues have studied the human immune ... Centers for Human Immunology. The original funding came soon ... the heels of the terrorist attacks of Sept. 11, ...
Breaking Biology News(10 mins):Insulin offers new hope for the treatment of acute pancreatitis 2Information Update - Allergens and food safety at school - What's in your child's lunch? 2Information Update - Allergens and food safety at school - What's in your child's lunch? 3$14.5 million grant awarded to continue anthrax studies 2
... team of engineers and scientists at the University of British ... the eye for controlled and on-demand release of drugs to ... the leading cause of vision loss among patients with diabetes. ... cells in the retina, which in its advanced stages can ...
... new biological evidence suggesting that the brain works differently ... own race than when memorizing a face from another ... to measure brain activity -- sheds light on a ... the most replicated psychology findings, the other-race effect finds ...
... onset of puberty is a critical moment for reaching ... are particularly high in countries where the HIV/AIDS epidemic ... Yet to date, the healthcare community in low-resource countries ... efforts on young women who are older and of ...
Cached Biology News:UBC researchers invent new drug delivery device to treat diabetes-related vision loss 2Clues to why 'they' all look alike 2Clues to why 'they' all look alike 3Clues to why 'they' all look alike 4Girl's Puberty Book Project provides an international model for promoting female health in Africa 2Girl's Puberty Book Project provides an international model for promoting female health in Africa 3
EMBP (FL-222)...
Rabbit anti-T-box 6...
...
... The PowerEase 500 Power Supply ... electrophoresis. It offers extensive programming ... four custom methods for you ... preferences. The simple intuitive PowerEase ...
Biology Products: